CTRI/2026/03/106163尚未招募3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED5 个研究点 分布在 1 个国家目标入组 274 人开始时间: 2026年3月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 274
- 试验地点
- 5
- 主要终点
- Change from baseline in Young Mania Rating Scale (YMRS) total score
研究概览
简要总结
KarXT (also referred to as BMS-986510)is a novel combined formulation of two drugs,
xanomeline tartrate and trospium chloride. The combination product is being developed to treat
psychiatric disorderswith a cholinergic mechanism to mitigate the peripheral side effects of
xanomeline, a muscarinic agonist, with trospiumchloride,a muscarinic antagonist.Trospium
chloride is a quaternary ammonium compound with a permanent cationic charge that limits its
ability to cross the blood-brain barrier. Due to this property, it does not interfere with the efficacy
of xanomeline despite competing with xanomeline for binding at peripheral receptors to reduce
the negative systemic side effects of xanomeline.
KarXT has the potential to provide a novel mechanism of action for the treatment ofbipolar mania.
Most antimanic agents approved in this century have the same orsimilar mechanisms of action,
perpetuating similar side effect profiles. The goal of this study is to demonstrate the efficacy of
KarXT in BP-I maniaormania with mixed features while exploringa differentiated side effect
profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Participants must be able and willing to sign and date an IRB/IEC-approved written ICF in accordance with regulatory, local, and institutional guidelines.
- •This ICF must be obtained before performing any protocol-related procedures that are not part of normal participant care.
- •Participant must be fluent in the language of the ICF to consent.
- •Type of Participant and Target Disease Characteristics 2) Primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on the DSM-5-TR criteria18 and confirmed by the Mini International Neuropsychiatric Interview (MINI, v7.0.2).
- •Experiencing an acute episode or relapse of mania or mania with mixed features (less than or equal to 3 weeks) based on DSM-5-TR criteria.18 4) Young Mania Rating Scale (YMRS) score of greater than or equal to 20 at Screening and at Baseline.
- •CGI-BP score of greater than or equal to 4 at screening and at baseline.
- •Requires hospitalization for acute exacerbation or relapse of mania.
- •Hospitalized voluntarily before or during Screening with a mania diagnosis not greater than 21 days before Screening.
- •(See Appendix 4 for country-specific requirements).
- •Body mass index greater than or equal to 18 and less than or equal to 40 kg/m
- •All psychotropic medications are washed out in no more than 14 days prior to the first dose of the study drug.
- •Able to comprehend and satisfactorily comply with protocol requirements per investigator judgment.
- •Age of Participant 11) Aged 18 (or the legal age of consent in the jurisdiction in which the study is taking place, if higher) to 65 years of age, inclusive, at the time of signing the ICF.
- •Reproductive Status · Note: The investigator or designee shall counsel individuals of childbearing potential (IOCBP) (as defined in APPENDIX 3) and male (as assigned at birth) participants who are sexually active with IOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.
- •· Note: The investigator or designee shall evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
- •· Note: Local laws and regulations may require the use of alternative and/or additional contraceptive methods (see APPENDIX 4).
- •Female (as assigned at birth) participants: Note: Female (as assigned at birth) participants who are individuals not of childbearing potential (INOCBP) (as defined in APPENDIX 3) must have documented proof.
- •Note: Participants who are INOCBP are exempt from contraceptive requirements.
- •a) IOCBP must have a negative highly sensitive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.
- •· Note: A positive serum pregnancy test or an ambiguous urine pregnancy test must be repeated and sent to the central laboratory (serum sample).
- •If either pregnancy test cannot be confirmed as negative (eg, an ambiguous result), the participant must be excluded from participation.
- •· Note: The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to potentially decrease the risk for inclusion of an individual with an undetected pregnancy.
- •b) IOCBP must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
- •· IOCBP are permitted to use hormonal contraceptive methods (as described in APPENDIX 3).
- •c) A female (as assigned at birth) is eligible to participate if they are not pregnant or breastfeeding and at least 1 of the following conditions applies: · Is an INOCBP OR · Is an IOCBP and using a contraceptive method that is highly effective (with a failure rate of less than 1 percent per year), with preferably user independent methods, as described in APPENDIX 3, during the intervention period and for at least 16 days, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.
- •Male (as assigned at birth) participants: Male (as assigned at birth) participants should maintain their usual practice regarding contraception (if any); however, no specific or additional contraceptive measures are required.
排除标准
- •Psychiatric Conditions 1) Primary diagnosis of BP-I where present mania is first manic episode. 2) Primary diagnosis of BP-I with rapid cycling (ie, greater than or equal to 4 distinct mood episodes in one year). 3) Any primary DSM-5-TR disorder other than BP-I with mania or mania with mixed features within 12 months before screening (ie, primary focus of treatment, confirmed using MINI version 7.0.2 at screening) including BP-I with depression (for previous 3 months only), BP-II disorder, major depressive disorder, and primary psychotic disorder, with the exception of mild anxiety disorders. 4) A DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within 12 months before screening (confirmed using MINI version 7.0.2 at screening), or current use as determined by urine toxicology screen or alcohol test. a) Participants who test positive for cannabis at screening may be permitted to enroll in consultation with the medical monitor if the participant’s pattern of use is not indicative of a substance use disorder. 5) Risk for suicidal behavior at screening as determined by the Investigator’s clinical assessment, and/or C-SSRS as confirmed by the following: a) Answer “Yes” on items 4 or 5 (C-SSRS.
- •ideation) within 6 months of screening, or between screening and baseline b) Answer “Yes” to any of the 5 items (C-SSRS.
- •behavior) within 12 months of screening or between screening and baseline. 6) Currently receiving oral psychoactive drugs that cannot be safely discontinued in the 14 days of screening prior to first dose, or whose half-life is greater than 14 days. For participants receiving monthly long-acting injectables (LAIs), the last injection cannot be less than five weeks before the first dose. Participants on LAIs with a two-month frequency cannot have had their last injection less than 10 weeks before the first dose of study treatment. Participants on LAIs with longer frequency periods will be excluded. 7) Lifetime history of any clozapine use. 8) Had a separate psychiatric hospitalization(s), unrelated to the current manic episode, within 90 days before screening. 9) YMRS total score less than 20 at baseline or greater than or equal to 20% reduction in YMRS from screening to baseline. 10) If, in the opinion of the investigator (and/or Sponsor), participant is unsuitable for enrollment in the study, or the participant has any finding that in the view of the investigator (and/or Sponsor) may compromise the safety of the participant or affect their ability to adhere to the protocol visit schedule or fulfill visit requirements. General Medical Conditions 11) History or present illness suggestive of uncontrolled hyperthyroidism. 12) History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months. 13) History or high risk of urinary retention, gastric retention, or untreated narrow-angle glaucoma. 14) History or presence of clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, gastrointestinal (eg, obstructive disorders [including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis]), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. 15) Participants with cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on the liver function test results. Note: Participants with any grade of hepatic impairment (Child-Pugh A or higher) will be excluded. 16) Active biliary disease (eg, symptomatic gallstones). Participants with other biliary histories are eligible and should be discussed with the medical monitor. 17) Participants are excluded from the study if any of the following criteria apply: a) History of bladder stones b) History of recurrent urinary tract infections c) Serum prostate-specific antigen greater than 10 ng/mL at Screening d) For male participants greater than or equal to 45 years of age, IPSS score of 5 (i.e., “almost always”) on items 1, 3, 5, or 6 e) For male participants greater than or equal to 45 years of age, an IPSS score greater than or equal to 9 for the sum of scores items 1, 3, 5, and 6 18) History of ischemic stroke within 12 months prior to Screening or any evidence of hemorrhagic stroke. 19) History of cerebral amyloid angiopathy, epilepsy, CNS neoplasm, unstable thyroid function, or unexplained syncope, delirium, cognitive disorders (eg, mild cognitive impairment and dementias). 20) History or presence of any of the following: a) New York Heart Association Class II or greater heart failure b) Grade 2 or greater angina pectoris (as measured by Canadian Cardiovascular Society [CCS] Grading) c) Sustained ventricular tachycardia d) Ventricular fibrillation e) Torsade de pointes Implantable cardiac defibrillator 21) Myocardial infarction within 6 months prior to Screening. 22) Risk of violent or destructive behavior. 23) Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks prior to the first dose of study drug (within 2 weeks for plasma only) and until at least 90 days after the end of the study. 24) Blood transfusion within 4 weeks prior to the first dose of study drug. 25) Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, medical history, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population. 26) Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, hepatitis B core antibody, or human immunodeficiency virus (HIV)-1 and HIV-2 antibody. Reproductive Status 27) Individuals who are pregnant, breastfeeding, or less than 3 months postpartum. Prior/Concomitant Therapy 28) Inability to comply with restrictions and prohibited treatments as listed in Section 7.7: Prior and Concomitant Therapy. 29) Pastor intended use of over-the-counter or prescription medication within 1 day or 1 half-life (whichever is longer) prior to dosing. If taking herbal/dietary supplements, subjects must be on a stable dose for at least 6 weeks prior to dosing. Ensure subjects are not taking supplements with known hepatotoxic ingredients. 30) Prior exposure to KarXT. 31) Anticipated use of lorazepam greater than allowed in protocol (see Section 7.7.1). 32) Use of any investigational medicine within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of the study drug. Physical and Laboratory Test Findings 33) Elevations in hepatic transaminases at screening greater than or equal to 3 × ULN for ALT and AST and/or bilirubin greater than 2× ULN, unless in the context of Gilbert’s syndrome. 34) Serum creatinine or blood urea nitrogen greater than ULN, at screening, or eGFR at screening less than 60 mL/min. 35) Blood pressure of greater than or equal to 160/100 mmHg (average of triplicate seated measures) at screening 36) Heart rate of greater than or equal to 110 bpm (average of triplicate seated measures) at screening. Allergies and Adverse Drug Reactions Allergies and Adverse Drug Reactions 37)History of any significant drug allergy (such as anaphylaxis). 38)History of allergy/hypersensitivity to any component (including excipients) of the study intervention or related compounds. Other Exclusion Criteria 39)Participant is an employee or first degree relative of the investigator, study site or BMS employee, with direct involvement in the proposed study or other studies under that direction. 40)Prisoners or participants who areinvoluntarily incarcerated. Note: Under certain specific circumstances and only in countries where local regulations permit, a person who has been imprisonedwhile on studymay be permitted to continue as a participant. Strict conditions apply.(See Appendix 4 for country-specific requirements).
结局指标
主要结局
Change from baseline in Young Mania Rating Scale (YMRS) total score
时间窗: 3 weeks
次要结局
- Change from baseline in Clinical Global Impression-Bipolar (CGI-BP) overall score(Week 3)
- Occurrence of response based on greater than or equal to 50 present decrease from baseline in YMRS score(Week 3)
- Occurrence of response based on CGI-BP change from baseline greater than or equal to 1(Week 3)
- Occurrence of treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and TEAEs leading to discontinuation(Treatment Period)
- Change from baseline in movement disorder scales (BARS, SAS, AIMS, IPSS for males greater than or equal to 45)(Week 3)
- Change in C-SSRS responses during treatment(Treatment Period)
研究者
Shilpi Sinha
Bristol-Myers Squibb India Pvt. Ltd.
研究点 (5)
Loading locations...
相似试验
已完成
3 期
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)Schizophrenia2024-510770-25-00Karuna Therapeutics Inc.65
招募中
3 期
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease2024-516363-92-00Bristol-Myers Squibb Services Unlimited Company93
招募中
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder2024-520165-32-00Bristol-Myers Squibb Services Unlimited Company77
招募中
3 期
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the
Treatment of Agitation Associated with Alzheimer’s Disease.2025-520612-34-00Bristol-Myers Squibb Services Unlimited Company90
尚未招募
3 期
Open-label Extension of KarXT and KarX EC for Agitation in Alzheimer DiseaseCTRI/2026/02/0104945Bristol Myers Squibb India Private Limited600